Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1634664
Author(s)
Hatz, Christoph; Cramer, Jakob P.; Vertruyen, André; Schwarz, Tino F.; von Sonnenburg, Frank; Borkowski, Astrid; Lattanzi, Maria; Hilbert, Anne Katrin; Della Cioppa, Giovanni; Leroux-Roels, Geert
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations
Journal
Vaccine
Volume
30
Number
32
Pages / Article-Number
4820-4827
Keywords
Influenza, H1N1, Pandemic, Adjuvant, MF59
Abstract
BACKGROUND: Modern cell-culture production techniques and the use of adjuvants helps to ensure that the global demand for pandemic influenza vaccine can be met. This study aimed to assess the immunogenicty and safety profiles of various cell-culture-derived A/H1N1 pandemic vaccine formulations in healthy adult and elderly subjects. METHODS: Adult (18-60 years) subjects (n=544) received vaccine either containing 3.75mug of antigen with half the standard dose of MF59((R)) (Novartis Vaccines and Diagnostics) adjuvant, 7.5mug antigen with a full dose of MF59, or a non-adjuvanted vaccine containing 15mug of antigen. Elderly (
